Phase 2 Peripheral Neuropathy Trial, Recruiting NCT06619860 Sponsor: Vertex Pharmaceuticals Incorporated Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Phase 2 Peripheral Neuropathy Trial, Recruiting

NCT06619860
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with either Type 1 or Type 2 diabetes
  • People whose HbA1c (a blood test that measures average blood sugar levels over about 3 months) is at or below 9%
  • People who have had pain in both legs or feet caused by diabetic nerve damage (a condition where nerves are affected in a symmetrical pattern, starting from the feet), lasting for at least 1 year

Who may not be able to join:

  • People whose nerve pain is caused by something other than diabetes
  • People who have a history of irregular heart rhythms that have required medication or other treatment to manage
  • People who have had a major heart or blood vessel event, such as a heart attack or stroke, within the past 12 months
  • Other criteria set out in the trial protocol may also apply (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 617-341-6777

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
18 October 2024
Est. completion
25 March 2027

Where this trial is recruiting

🇨🇦 Canada 🇫🇷 France 🇩🇪 Germany 🇮🇹 Italy 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov